FASgen awarded $2.1 million grant for obesity research

FASgen’s novel small molecule compounds are designed to limit the appetite and to increase the metabolic breakdown of excess fat stored in the body. Studies in mice reveal that weight loss is achieved by modifying physiologic mechanisms that have not been the targets of previous anti-obesity therapy.

“Our primary task at this point is to take our lead compounds into human trials to confirm the fact that we can cause a selective reduction in body fat and that these compounds can be administered safely over a prolonged period of time,” said Dr Albert Owens, FASgen’s president and founder.